IN2012DN02018A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02018A
IN2012DN02018A IN2018DEN2012A IN2012DN02018A IN 2012DN02018 A IN2012DN02018 A IN 2012DN02018A IN 2018DEN2012 A IN2018DEN2012 A IN 2018DEN2012A IN 2012DN02018 A IN2012DN02018 A IN 2012DN02018A
Authority
IN
India
Prior art keywords
hedgehog
taxane
inhibits
administering
cancer
Prior art date
Application number
Inventor
Chunlin Tao
Neil P Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of IN2012DN02018A publication Critical patent/IN2012DN02018A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway.
IN2018DEN2012 2009-08-25 2010-08-25 IN2012DN02018A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23681309P 2009-08-25 2009-08-25
PCT/US2010/046684 WO2011025838A1 (en) 2009-08-25 2010-08-25 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN02018A true IN2012DN02018A (en) 2015-07-31

Family

ID=43628371

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2018DEN2012 IN2012DN02018A (en) 2009-08-25 2010-08-25

Country Status (26)

Country Link
US (2) US20130045240A1 (en)
EP (2) EP2470173B1 (en)
JP (1) JP2013503174A (en)
KR (1) KR20120053052A (en)
CN (1) CN102573832B (en)
AU (1) AU2010286670B2 (en)
BR (1) BR112012004149A2 (en)
CA (1) CA2772301A1 (en)
CR (1) CR20120115A (en)
DK (1) DK2470173T3 (en)
ES (1) ES2577024T3 (en)
HR (1) HRP20160551T8 (en)
HU (1) HUE029094T2 (en)
IL (1) IL218316A (en)
IN (1) IN2012DN02018A (en)
MX (1) MX340670B (en)
MY (1) MY162514A (en)
NI (1) NI201200030A (en)
NZ (1) NZ598588A (en)
PL (1) PL2470173T3 (en)
PT (1) PT2470173E (en)
RU (1) RU2561055C2 (en)
SG (2) SG10201609290PA (en)
UA (1) UA110196C2 (en)
WO (1) WO2011025838A1 (en)
ZA (1) ZA201201531B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
LT1585548T (en) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
NZ595313A (en) 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
CA2880727C (en) * 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
KR20150002886A (en) * 2007-03-07 2015-01-07 아브락시스 바이오사이언스, 엘엘씨 Nanoparticle comprising rapamycin and albumin as anticancer agent
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
EP2942346B1 (en) 2009-02-17 2020-05-06 Syntrix Biosystems, Inc. Pyridinecarboxamides as cxcr2 modulators
PT2419732T (en) 2009-04-15 2019-12-24 Abraxis Bioscience Llc Prion-free nanoparticle compositions and methods
PL2552438T3 (en) 2010-03-26 2016-12-30 METHODS OF TREATMENT OF Hepatocellular Cancer
RU2016119999A (en) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи METHODS FOR TREATING ONCOLOGICAL DISEASES
BR112012024590A2 (en) 2010-03-29 2016-05-31 Abraxis Bioscience Inc methods of enhancing drug release and efficacy of therapeutic agents
CA2797694A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
SG186109A1 (en) * 2010-06-02 2013-01-30 Abraxis Bioscience Llc Methods of treating bladder cancer
JP6257324B2 (en) * 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー How to treat pancreatic cancer
EP3056201A1 (en) * 2010-06-07 2016-08-17 Abraxis BioScience, LLC Combination therapy methods for treating proliferative diseases
US8779149B2 (en) * 2010-08-23 2014-07-15 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as CXCR2 modulators
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
SMT201900502T1 (en) 2011-12-14 2019-11-13 Abraxis Bioscience Llc Use of polymeric excipients for lyophilization or freezing of particles
US9248128B2 (en) 2012-01-27 2016-02-02 New York University Method for enhancing remyelination using GLI1 inhibitors
CN103570625A (en) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-aryl-heteroaryl)-4-aryl-aryl carboxamide and analog as hedgehog pathway inhibitors and application thereof
WO2014062511A1 (en) * 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
WO2014087413A1 (en) * 2012-12-03 2014-06-12 Vishwa Vidya Peetham University Amrita Nanoparticles comprising sorafenib
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (en) * 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー How to treat lung cancer
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
WO2014144747A1 (en) * 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9045477B2 (en) * 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2014179678A1 (en) * 2013-05-03 2014-11-06 Angiostrass Llc Methods of treating cancer and angioproliferative disorders
RU2681849C2 (en) * 2013-06-05 2019-03-13 Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ Heterocyclic derivatives and use thereof
TW201506024A (en) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 Tricyclic carboxamide derivatives as potent ROCK inhibitors
JP6522602B2 (en) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tricyclic pyrido-carboxamide derivatives as ROCK inhibitors
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
AR097685A1 (en) * 2013-09-17 2016-04-06 Genentech Inc METHODS OF USE OF ANTI-LGR5 ANTIBODIES
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN111170998B (en) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 Pyrimidine or pyridine compound, preparation method and medical application thereof
KR20160066490A (en) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 Heterocyclic derivatives and use thereof
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CA2986083A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Efflux-pump inhibitors and therapeutic uses thereof
JP6987644B2 (en) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー How to treat epithelioid cell tumors
CN106421786A (en) * 2015-08-06 2017-02-22 复旦大学 Hedgehog pathway inhibitor and nanometer drug delivery system pharmaceutical composition and uses thereof
JP2018052878A (en) * 2016-09-29 2018-04-05 第一三共株式会社 Pyridine compounds
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
RU2020134124A (en) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY INTRODUCTION OF NANOPARTICLES CONTAINING mTOR AND ALBUMIN INHIBITOR
JP2022543021A (en) * 2019-05-29 2022-10-07 ネルム コーポレーション Methods and uses for treating cancer
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
CN112755042A (en) * 2019-11-06 2021-05-07 绍兴维帆生物技术有限公司 Method for treating leukemia by using antitumor drugs in combination
KR102526793B1 (en) * 2021-11-03 2023-04-28 주식회사 에스엔바이오사이언스 Method for preparing albumin bound taxane nanoparticles with improved particle size distribution maintenance stability
WO2025120550A1 (en) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 Intermediate compound used in preparing heterocycle derivative, method for preparing intermediate compound, and method for preparing heterocycle derivative using same
WO2025120551A1 (en) * 2023-12-08 2025-06-12 제이더블유중외제약 주식회사 Intermediate compound used in preparing heterocycle derivative, method for preparing same, and method for preparing heterocycle derivative using same
CN120177781B (en) * 2025-05-22 2025-08-12 南京师范大学 Biosensor and its application and method for high-throughput screening of zingerone-producing bacteria

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
KR100904931B1 (en) * 1997-06-27 2009-06-29 아브락시스 바이오사이언스, 엘엘씨 Nanoparticles and Method for the Preparation Thereof
EP1133519B1 (en) 1998-11-02 2008-08-13 Curis, Inc. Functional antagonists of hedgehog activity
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
AU767066B2 (en) 1999-03-03 2003-10-30 Curis, Inc. Methods of modulating lipid metabolism and storage
AU782493B2 (en) 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US20050192262A1 (en) * 2001-03-13 2005-09-01 Tomas Hagstrom Treatment of tumours
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
ITMI20020680A1 (en) * 2002-03-29 2003-09-29 Acs Dobfar Spa IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING
ATE404200T1 (en) 2002-04-22 2008-08-15 Univ Johns Hopkins Med MODULATORS OF HEDGEHOG SIGNAL PATHS, COMPOSITIONS AND RELATED USES
LT1585548T (en) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
FR2850022B1 (en) * 2003-01-22 2006-09-08 Centre Nat Rech Scient NOVEL USE OF MIFEPRISTONE AND ITS DERIVATIVES AS MODULATORS OF THE HEDGEHOG PROTEIN SIGNALING PATH AND ITS APPLICATIONS
PE20050206A1 (en) * 2003-05-26 2005-03-26 Schering Ag PHARMACEUTICAL COMPOSITION CONTAINING AN INHIBITOR OF HISTONE DEACETILASE
US20070281040A1 (en) * 2004-09-30 2007-12-06 The University Of Chicago Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents
CA2587489C (en) * 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
NZ595313A (en) * 2005-02-18 2013-03-28 Abraxis Bioscience Llc The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases
KR101643416B1 (en) 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009514889A (en) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Methods of using SAHA and bortezomib to treat cancer
AR054215A1 (en) * 2006-01-20 2007-06-13 Eriochem Sa A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT
WO2008121102A2 (en) 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
DE102006038747A1 (en) 2006-08-17 2008-03-20 Khs Ag Sealing arrangement for a rotary bearing device
JP4897518B2 (en) 2007-03-02 2012-03-14 株式会社ニチベイ Blind operating device
JP5577104B2 (en) * 2007-03-14 2014-08-20 エクセリクシス パテント カンパニー エルエルシー Inhibitors of the hedgehog pathway
JP5550352B2 (en) * 2007-03-15 2014-07-16 ノバルティス アーゲー Organic compounds and uses thereof
EP3326630A3 (en) 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
JP5373777B2 (en) * 2007-06-07 2013-12-18 アイアールエム・リミテッド・ライアビリティ・カンパニー Biphenylcarboxamide derivatives as hedgehog pathway modulators
US20090123932A1 (en) * 2007-11-09 2009-05-14 Anne-Marie Mes-Masson Quantitative test to detect disease progression markers of epithelial ovarian cancer patients
CN101918420A (en) * 2007-12-27 2010-12-15 无限药品股份有限公司 cancer treatment
EP2235063B1 (en) * 2007-12-28 2015-09-02 Genentech, Inc. Anti-hedgehog antibodies

Also Published As

Publication number Publication date
MY162514A (en) 2017-06-15
PT2470173E (en) 2016-06-15
SG10201609290PA (en) 2016-12-29
EP2470173A1 (en) 2012-07-04
EP2470173B1 (en) 2016-04-27
NZ598588A (en) 2014-05-30
CN102573832B (en) 2015-07-22
RU2012111235A (en) 2013-10-10
EP2470173A4 (en) 2013-06-19
HRP20160551T1 (en) 2016-09-23
HK1172550A1 (en) 2013-04-26
ZA201201531B (en) 2013-05-29
CN102573832A (en) 2012-07-11
MX2012002460A (en) 2012-05-08
ES2577024T3 (en) 2016-07-12
CR20120115A (en) 2012-09-04
UA110196C2 (en) 2015-12-10
IL218316A0 (en) 2012-04-30
WO2011025838A1 (en) 2011-03-03
HUE029094T2 (en) 2017-02-28
RU2561055C2 (en) 2015-08-20
SG178873A1 (en) 2012-04-27
PL2470173T3 (en) 2016-11-30
CA2772301A1 (en) 2011-03-03
DK2470173T3 (en) 2016-06-06
US20130045240A1 (en) 2013-02-21
AU2010286670A1 (en) 2012-03-29
US20140072630A1 (en) 2014-03-13
IL218316A (en) 2016-04-21
KR20120053052A (en) 2012-05-24
JP2013503174A (en) 2013-01-31
MX340670B (en) 2016-07-20
EP3103452A1 (en) 2016-12-14
NI201200030A (en) 2012-12-06
HRP20160551T8 (en) 2016-11-18
BR112012004149A2 (en) 2016-03-22
AU2010286670B2 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
IN2012DN02018A (en)
MY162903A (en) Methods of treatment of pancreatic cancer
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
PH12012502399A1 (en) Combination therapy methods for treating proliferative diseases
NZ700759A (en) Combination therapy for treating cancer
PH12016502066A1 (en) Methods of treating bladder cancer
MX2020010535A (en) Methods of treating cancer.
CR20120202A (en) METHODS AND COMPOSITIONS TO TREAT CANCER
MX2017007321A (en) Combination therapies.
MX2016007351A (en) COMBINATION THERAPY TO TREAT CANCER.
MX2009009537A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent.
MX2013011908A (en) Compositions and therapeutic uses of ikk-related kinase epsilon and tankbinding kinase 1 inhibitors.
PH12013502487A1 (en) Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
GB201114051D0 (en) Compounds and their uses
UA103614C2 (en) Medicinal composition for treating hepatic cancer which comprises a kinase inhibitor. combined with glypican 3 antibody
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
MX2010009697A (en) Improved anticancer treatments.
MX2014010749A (en) Gynecologic composition to treat vulvar vestibulitis.
TNSN08062A1 (en) Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin
HK1183815A (en) Methods of treatment of pancreatic cancer
HK1183814A (en) Combination therapy methods for treating proliferative diseases
UA110795C2 (en) Method of treatment of pancreatic cancer
TN2010000463A1 (en) Compositions and methods for preparing and using same